Human immunodeficiency virus-related non-Hodgkin lymphoma - Activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients

Citation
M. Spina et al., Human immunodeficiency virus-related non-Hodgkin lymphoma - Activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients, CANCER, 92(1), 2001, pp. 200-206
Citations number
20
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER
ISSN journal
0008-543X → ACNP
Volume
92
Issue
1
Year of publication
2001
Pages
200 - 206
Database
ISI
SICI code
0008-543X(20010701)92:1<200:HIVNL->2.0.ZU;2-Q
Abstract
BACKGROUND. The prognosis of patients with human immunodeficiency virus (HI V)-related non-Hodgkin lymphoma (NHL) is poor. In fact, despite a high comp lete response (CR) rate, approximately 50% of these patients die from progr essive lymphoma. METHODS. From November 1994 to April 2000, the authors treated 40 patients with resistant or recurrent HIV-related NHL with a 96-hour continuous intra venous infusion of cyclophosphamide (187.5 mg/m(2) per day), doxorubicin (1 2.5 mg/m(2) per day), and etoposide (60 mg/m(2) per day). RESULTS. The median number of cycles administered was two (range, one to si x cycles). A CR was documented in 4 of 40 patients (10%), and a partial. re mission (PR) was documented in 7 of 40 patients (18%). The CR median durati on was 6 months (range, 4-30+ months), whereas PRs lasted for 5 months (ran ge, 2-8 months). The overall median survival was 4 months (range, < 1-33 mo nths), and the median survival for responding patients was 10 months. CONCLUSIONS. The current data confirm that infusional cyclophosphamide, dox orubicin, and etoposide is active in patients with refractory or recurrent HIV-related NHL. However, the median survival of these patients remains poo r, and the other innovative approaches should be used. Cancer 2001;92:200-6 . (C) 2001 American Cancer Society.